<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2310">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03076814</url>
  </required_header>
  <id_info>
    <org_study_id>PRO27634</org_study_id>
    <nct_id>NCT03076814</nct_id>
  </id_info>
  <brief_title>Functional Muscle Ischemia With Tadalafil Treatment in Becker Muscular Dystrophy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      the Investigator will test the hypothesis that short term PDE5A inhibition (with tadalafil)
      will reduce post-exercise edema by MRI in males with Becker Muscular Dystrophy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Becker muscular dystrophy (BMD) is a rare, progressive and fatal muscle disease. Tadalafil
      is approved by the FDA for the treatment of erectile dysfunction and pulmonary hypertension.
      This class of medication improves muscle blood flow in a mouse model of muscular dystrophy,
      prevents post-exercise muscle edema, and alleviates post-exercise muscle fatigue. To begin
      to translate this work from the mouse into actual patients with muscular dystrophy, the
      Investigator group recently demonstrated that a single dose of tadalafil can improve blood
      flow regulation in boys with Duchenne muscular dystrophy and men with BMD. the Investigator
      now wish to test the hypothesis that acute treatment with Tadalafil can prevent
      post-exercise muscle edema in men with BMD.

      the Investigator will recruit men with BMD, and healthy age-matched controls, ages 15-55y
      who are ambulatory and without heart failure.

      Visit 1: Participants will undergo informed consent, physical exam and medical history
      screening, electrocardiogram, blood pressure monitoring, blood chemistry testing,
      echocardiogram (ejection fraction measurement), and evaluation of skeletal muscle blood
      flow. Patients, but not controls, will also undergo a muscle biopsy.

      Visit 2 - 4: Participants will undergo baseline magnetic resonance imaging of the forearm
      muscle, followed by rhythmic forearm muscle exercise (handgrip). MRI will then be repeated
      2-, 4-, 24-, and 48 hours following the rhythmic handgrip exercise.

      Patients with BMD will then be randomized in a 3:1 fashion to tadalafil vs. placebo.

      Visit 5-7: Using a standard double-blind cross-over design, patients will be treated with
      either tadalafil or placebo. Magnetic resonance imaging of the forearm muscle will be
      performed to establish baseline measurements. Patients will then repeat the rhythmic
      handgrip exercise protocol performed on Visit 2, followed by MRI 2-, 4-, 24-, and 48 hours
      following exercise.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in post-exercise muscle edema by MRI.</measure>
    <time_frame>Pre vs. 48 hours post treatment change</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Becker Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Effects of tadalafil to alleviate post-exercise muscle edema by MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Effects of placebo on post-exercise muscle edema by MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patient with BMD -

        Inclusion Criteria:

          -  diagnosis of BMD confirmed by muscle biopsy or DNA analysis

          -  age 15-55 years of age

          -  ambulatory

          -  no clinical evidence of heart failure

        Exclusion Criteria:

          -  hypertension, diabetes, or heart failure by standard clinical criteria

          -  elevated BNP (brain natriuretic peptide) level (&gt;100 pg/ml)

          -  left ventricular ejection fraction &lt; 50%

          -  wheelchair bound

          -  cardiac rhythm disorder, specifically: rhythm other than sinus, sinoventricular
             tachycardia, atrial fibrillation, ventricular tachycardia

          -  continuous ventilatory support

          -  liver disease

          -  renal impairment

          -  contraindications to tadalafil (use of nitrates, alpha-blockers, Cytochrome P450
             (CYP3A )inhibitors, amlodipine, or other phosphodiesterase 5A inhibitors)

        Healthy Control Participants -

        Inclusion Criteria:

          -  age 15-55 years of age

          -  ambulatory

          -  no clinical evidence of heart failure

        Exclusion Criteria:

          -  hypertension, diabetes, or heart failure by standard clinical criteria

          -  elevated BNP (brain natriuretic peptide) level (&gt;100 pg/ml)

          -  left ventricular ejection fraction &lt; 50%

          -  cardiac rhythm disorder, specifically: rhythm other than sinus, sinoventricular
             tachycardia, atrial fibrillation, ventricular tachycardia

          -  liver disease

          -  renal impairment

          -  unsatisfactory completion of the sympatholysis protocol

          -  BMI &lt; 35
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 6, 2017</lastchanged_date>
  <firstreceived_date>September 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Ron Victor</investigator_full_name>
    <investigator_title>Director, Hypertension Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
